Company profile for Anavex Life Sciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. Anavex utilizes precision genetic medicine to treat severe and devastating neurological disorders and is focusing on rare diseases with no available therapy (Rett syndrome) as well as neurodegenerative diseases that are on the rise due to aging population...
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. Anavex utilizes precision genetic medicine to treat severe and devastating neurological disorders and is focusing on rare diseases with no available therapy (Rett syndrome) as well as neurodegenerative diseases that are on the rise due to aging populations (Parkinson's Disease and Alzheimer's Disease)

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
New York City, NY 10019
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/12/3204857/29248/en/Anavex-Life-Sciences-Provides-Update-on-Regulatory-Review-in-the-EU-for-Blarcamesine-to-Treat-Early-Alzheimer-s-Disease.html

GLOBENEWSWIRE
12 Dec 2025

https://www.globenewswire.com/news-release/2025/11/26/3195056/29248/en/Anavex-Life-Sciences-to-Present-Oral-Blarcamesine-Data-at-the-18th-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference.html

GLOBENEWSWIRE
26 Nov 2025

https://www.globenewswire.com/news-release/2025/11/25/3194241/29248/en/Anavex-Life-Sciences-Reports-Fiscal-2025-Fourth-Quarter-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
25 Nov 2025

https://www.globenewswire.com/news-release/2025/11/19/3190832/29248/en/Anavex-Life-Sciences-to-Present-at-the-44TH-ANNUAL-J-P-MORGAN-Healthcare-Conference.html

GLOBENEWSWIRE
19 Nov 2025

https://www.globenewswire.com/news-release/2025/11/18/3189886/29248/en/Anavex-Life-Sciences-to-Announce-Fiscal-2025-Fourth-Quarter-Financial-Results-on-Tuesday-November-25-2025.html

GLOBENEWSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/11/14/3188222/29248/en/Anavex-Life-Sciences-Provides-Regulatory-Update-on-Blarcamesine-for-Early-Alzheimer-s-Disease.html

GLOBENEWSWIRE
14 Nov 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty